Walgreens Boots Alliance is in talks to sell itself to private equity firm Sycamore Partners, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore
Walgreens Boots Alliance (WBA) concluded the recent trading session at $8.56, signifying a +1.06% move from its prior day's close.
SAN DIEGO, CA / ACCESSWIRE / December 5, 2024 / Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Warner Bros. Discovery, Inc. (NASDAQ:WBD) securities between February 23, 2024 and August 7, 2024.
Is Walgreens' High-Yielding Dividend Safe?
Walgreens faces ongoing financial challenges, including a potential future dividend cut, despite recent progress in cost-cutting and debt reduction. The company's 11.9% dividend yield is not covered by free cash flow, with legal fees and operational costs impacting cash flow sustainability. Management's turnaround efforts, including store closures and asset monetization, show promise but will take years to fully materialize.
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $9.03, representing a +0.22% change from its previous close.
Walgreens' recent 57% stock decline, dividend cut, and poor reinvestment opportunities indicate it's not in deep value territory and may face further pain. WBA's high debt levels, with free cash flow dropping drastically, suggest another dividend cut is likely despite their capital allocation plan. The Company's focus on debt reduction and reinvestment is problematic due to poor historical returns on invested capital.
The struggling pharmacy retailer still has a tough road ahead.
Walgreens Boots Alliance's forward yield hovers around 10.8%, the highest among the S&P 500 index. Such yield raises concerns about a potential dividend trap due to bleak growth prospects and financial struggles, as reported in its recent Q4 earnings. Its Q4 earnings reveal significant challenges, including store closures and a bleak EPS growth outlook.
Shareholders were spooked about a new threat to the company's core business; a fresh dividend declaration didn't help.
Walgreens recently announced it would be closing 1,200 stores over the next few years.